INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///
05/18/2022

Protocol for Drug Screening of Patient-Derived Tumor Organoids Using High-Content Fluorescent Imaging

STAR Protocols, Tempus-authored Manuscript
Authors Brian M. Larsen, Andrea Cancino, Jenna M. Shaxted, and Ameen A. Salahudeen

Summary

High-content imaging of tumor organoids (TOs) treated with therapeutic agents provides detailed cell viability readouts at the organoid level. In contrast, most used protocols provide one number per well. While requiring the use of inverted microscopy with an automated stage, this protocol can provide critical information about heterogeneous responses of TOs to various treatments. This protocol describes a technique for culturing and drug testing TOs using fluorescent indicators of cell viability with high reproducibility.

VIEW THE PUBLICATION